Skip to content
A clearer view of the evidence.

THE LATEST IN OUR COLLECTION

Research news.

Browse captured papers, newly posted trial results and dated FDA notices.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Sources captured Oct 21, 2026. Not a live or comprehensive feed.

How dates & coverage work

Newest captured updates

Loading search and filters…

  1. FDA notice dated
    FDA announcementFDA

    FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer

    FDA approved nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin for adults with BCG-unresponsive non-muscle invasive bladder cancer . This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors to include patients with high-grade papillary-only tumors.

  2. Results first posted
    Trial resultsClinicalTrials.gov

    Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

    NCT03881488 · Locally Advanced Solid Tumor · Metastatic Cancer · Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma · Melanoma · Head and Neck Cancer · PHASE1

    Found by registry condition search · Source-reported results, not necessarily final

  3. Results first posted
    Trial resultsClinicalTrials.gov

    Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

    NCT04256707 · Non-Small Cell Lung Carcinoma (NSCLC) · Colorectal Cancer (CRC) · Other Solid Tumors · PHASE1 · PHASE2

    Found by registry condition search · Source-reported results, not necessarily final

  4. FDA notice dated
    FDA announcementFDA

    FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer

    FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.

  5. Results first posted
    Trial resultsClinicalTrials.gov

    Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

    NCT03213652 · Advanced Malignant Solid Neoplasm · Malignant Solid Neoplasm · Recurrent Ependymoma · Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Recurrent Hepatoblastoma · Recurrent Langerhans Cell Histiocytosis · Recurrent Malignant Germ Cell Tumor · Recurrent Malignant Glioma · Recurrent Malignant Solid Neoplasm · Recurrent Medulloblastoma · Recurrent Neuroblastoma · Recurrent Non-Hodgkin Lymphoma · Recurrent Osteosarcoma · Recurrent Primary Central Nervous System Neoplasm · Recurrent Rhabdoid Tumor · Recurrent Rhabdomyosarcoma · Recurrent Soft Tissue Sarcoma · Refractory Ependymoma · Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Refractory Hepatoblastoma · Refractory Langerhans Cell Histiocytosis · Refractory Malignant Germ Cell Tumor · Refractory Malignant Glioma · Refractory Malignant Solid Neoplasm · Refractory Medulloblastoma · Refractory Neuroblastoma · Refractory Non-Hodgkin Lymphoma · Refractory Osteosarcoma · Refractory Primary Central Nervous System Neoplasm · Refractory Rhabdoid Tumor · Refractory Rhabdomyosarcoma · Refractory Soft Tissue Sarcoma · Wilms Tumor · PHASE2

    Found by registry condition search · Source-reported results, not necessarily final

  6. Results first posted
    Trial resultsClinicalTrials.gov

    Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

    NCT04439227 · Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm · Refractory Lymphoma · Refractory Malignant Solid Neoplasm · Refractory Multiple Myeloma · PHASE2

    Found by registry condition search · Source-reported results, not necessarily final

  7. Results first posted
    Trial resultsClinicalTrials.gov

    Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

    NCT03082534 · HNSCC · Lip SCC · Oral Cavity Cancer · Oropharynx Cancer · Larynx Cancer · Hypopharynx Cancer · Nasopharynx Cancer · Sinonasal Carcinoma · Cutaneous Squamous Cell Carcinoma · Head and Neck Neoplasms · Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · PHASE2

    Found by registry condition search · Source-reported results, not necessarily final

  8. Results first posted
    Trial resultsClinicalTrials.gov

    Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

    NCT03278782 · Recurrent Anaplastic Large Cell Lymphoma · Recurrent Angioimmunoblastic T-Cell Lymphoma · Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides · Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Refractory Anaplastic Large Cell Lymphoma · Refractory Angioimmunoblastic T-Cell Lymphoma · Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma · Refractory Mycosis Fungoides · Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified · Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · PHASE1 · PHASE2

    Found by registry condition search · Source-reported results, not necessarily final

  9. Results first posted
    Trial resultsClinicalTrials.gov

    Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

    NCT04074746 · Recurrent Anaplastic Large Cell Lymphoma · Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Classic Hodgkin Lymphoma · Recurrent Mycosis Fungoides · Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified · Refractory Anaplastic Large Cell Lymphoma · Refractory B-Cell Non-Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma · Refractory Mycosis Fungoides · Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified · PHASE1 · PHASE2

    Found by registry condition search · Source-reported results, not necessarily final

Search stays in your browser. A newer date does not mean stronger evidence or a better treatment.

About this research feed

Papers are citations captured from NCI source reading, not a comprehensive literature search. Titles and bibliographic metadata are preserved; abstracts and full texts are not included. Corrections, retractions and concerns present in the snapshot are flagged; missing flags do not establish that a paper is unaffected.

Trial entries use the date results were first posted, not the date a registry record was last updated. Dates marked estimated by the source stay explicitly labelled. An administrative update is not presented as new findings. Cited trials and condition-search discoveries are labelled separately; this is not a representative sample of all trials.

Papers use the supplied online-publication date when available, otherwise the supplied publication date. Partial dates stay partial and sort after precisely dated entries in the same month or year. An FDA notice is not confirmation of current approved use or a treatment recommendation. Safety notices are distinct from approvals.

0 records without a usable event date and 0 with dates after the release cutoff are not placed in the dated feed. The original records remain in the source library.